1. Home
  2. XYF vs MGNX Comparison

XYF vs MGNX Comparison

Compare XYF & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

XYF

X Financial each representing six

HOLD

Current Price

$4.89

Market Cap

186.4M

Sector

Finance

ML Signal

HOLD

Logo MacroGenics Inc.

MGNX

MacroGenics Inc.

HOLD

Current Price

$4.39

Market Cap

220.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
XYF
MGNX
Founded
2014
2000
Country
China
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
186.4M
220.6M
IPO Year
2018
2013

Fundamental Metrics

Financial Performance
Metric
XYF
MGNX
Price
$4.89
$4.39
Analyst Decision
Buy
Analyst Count
0
5
Target Price
N/A
$5.00
AVG Volume (30 Days)
133.3K
1.3M
Earning Date
05-18-2026
05-08-2026
Dividend Yield
11.34%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$149,500,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$3.19
P/E Ratio
$0.90
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.30
$1.19
52 Week High
$20.36
$4.64

Technical Indicators

Market Signals
Indicator
XYF
MGNX
Relative Strength Index (RSI) 53.62 66.06
Support Level $4.86 $1.48
Resistance Level $5.12 N/A
Average True Range (ATR) 0.31 0.33
MACD -0.02 0.08
Stochastic Oscillator 67.33 85.75

Price Performance

Historical Comparison
XYF
MGNX

About XYF X Financial each representing six

X Financial is a Cayman Islands-based technology-driven personal finance company. Along with its subsidiaries, the firm provides diversified investment opportunities to investors in China through its wealth management platform, Xiaoying Wealth Management. Loan products offered by the company include Xiaoying Card Loan, Xiaoying Preferred Loan, and Xiaoying Housing Loan. The company generates revenue from loan facilitation service, post-origination service, and guarantee services provided.

About MGNX MacroGenics Inc.

Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.

Share on Social Networks: